Mather Group
SUPN icon

Mather Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Mather Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.08K Buy
118
+8
+7% +$365 ﹤0.01% 1808
2026
Q2 		$5.12K Hold
110
– – ﹤0.01% 1617
2026
Q1 		$5.69K Buy
+110
New +$5.6K ﹤0.01% 1554
2025
Q4 		– Sell
-270
Closed -$12.9K – 1534
2025
Q3 		$12.9K Buy
+270
New +$10.9K ﹤0.01% 1214
2025
Q2 		– Sell
-270
Closed -$8.84K – 1596
2025
Q1 		$8.84K Buy
270
+160
+145% +$5.67K ﹤0.01% 1285
2024
Q4 		$3.98K Hold
110
– – ﹤0.01% 1416
2024
Q3 		$3.43K Sell
110
-140
-56% -$4.37K ﹤0.01% 1368
2024
Q2 		$8.53K Hold
250
– – ﹤0.01% 1493
2024
Q1 		$7.24K Buy
+250
New +$7.44K ﹤0.01% 1278

Other funds holding SUPN

Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Campbell Newman Asset Management
Campbell Newman Asset Management Milwaukee, Wisconsin $1.33B AUM 26.63% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
James Investment Research
James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return

Mather Group's SUPN Position: Q3 2026 in Review

Mather Group increased its Supernus Pharmaceuticals (SUPN) stake by 7.3% in Q3 2026, buying an estimated $365 and bringing the position to 118 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

Mather Group first reported a position in SUPN in Q1 2024 and has held it in 9 quarters since. The position peaked at $12.9K in Q3 2025. 51 funds tracked by Wall St. Rank hold SUPN as of Q3 2026.

  • Mather Group held 118 shares of Supernus Pharmaceuticals worth $5.08K as of Q3 2026.
  • Mather Group bought 8 Supernus Pharmaceuticals shares in Q3 2026, an estimated $365.
  • Supernus Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1808 holding.
  • Mather Group first reported a position in Supernus Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Mather Group's Supernus Pharmaceuticals position peaked at $12.9K in Q3 2025.
  • 51 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.